
23th Juin 2008
Biocentury, The Bernstein Report on BioBusiness.
Read More >
27th Octobre 2006
Article de l'agefi.
Read More >
Diagnoplex is leveraging its proprietary molecular platform capabilities to develop non-invasive cancer screening tests. Its lead program targets colorectal cancer (CRC). Diagnoplex’s non-invasive CRC test “COLOX” will be made available as a ready-to-use clinical laboratory kit. Unlike current invasive and uncomfortable screening tools for colorectal cancer, Diagnoplex’s test is derived from peripheral blood samples that can be routinely and accurately analyzed using standard laboratory equipment. COLOX addresses important psychological, cost and scalability challenges to the effective screening of colorectal cancer, the cancer killer number one among non-smokers.
COLOX is being developed as a highly accurate non-invasive colorectal cancer screening test that is easy to use in clinical practice and allows systematic screening of the millions of people at risk worldwide. It does not require hospitalization, its results are accurate and reproducible, and targets only patients referred for colonoscopy. Based on its unique features, COLOX has the potential to become “the” pre-colonoscopy gold standard.
Read More >
^ Top | Copyright © Diagnoplex.com